Introducing the Oncotype DX® Test
The Oncotype DX® Breast Cancer test is a multigene diagnostic test that determines the individual risk of cancer recurrence in early-stage invasive breast cancer and identifies patients with minimal, if any, likelihood of benefit, and patients with substantial likelihood of benefit from chemotherapy. The Oncotype DX® test reveals the underlying tumour biology to help guide treatment decisions.
The Oncotype DX® test analyses the activity of 21 genes from the breast cancer tumour to provide an individual Recurrence Score® result, which is unique to the biology of a patient’s cancer.
The Oncotype DX® test should be used when the benefit of chemotherapy for a patient is uncertain. The test increases both the patient and her doctor’s confidence in treatment decisions.
Visit these pages for further information on the Oncotype DX® test, cancer-related terminology, and FAQs.